Why Boston Scientific Corporation’s (BSX) Stock Is Down 6.08%
As of Wednesday, July 29, Boston Scientific Corporation’s BSX share price has dipped by 6.08%, which has investors questioning if this is right time to buy.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Michael Rose
Cynthia McLaughlin
Cynthia McLaughlin
Jenna Brashear
| Share Statistics | BSX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $69,457.4 | $337.2 | 95% |
|
| Shares Out (Mil) | 1,495.0 | 41.9 | 96% |
|
| Institutional Ownership | 99.8% | 77.8% | 94% |
|
| Float (Mil) | 1,482.4 | 34.7 | 94% |
|
| Beta | 0.58 | 0.85 | 33% |
|
| Avg Daily Volume (000s) | 22,937 | 278 | 99% |
|
| Price Change (52-week) |
(56.2%) | 58.7% | 13% |
|
| Growth | BSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.2% | 11.8% | 73% |
|
| Net Income (5yr) | 106.3% | (5.8%) | 99% |
|
| EPS (5yr) | 91.8% | 11.4% | 99 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 1.2% | (16.3%) | 66% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 23 | 26 | 27 | |
| Current EPS | $0.805 | $3.304 | $3.443 | |
| Month Ago EPS | $0.839 | $3.363 | $3.721 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.845 | $3.378 | $3.764 | |
| Year/Year Chg | (10.6%) | 70.3% | 95.8% | |
| Financials | BSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $20,614 | $152 | 91% |
|
| Net Income (TTM) (Mil) | $3,565 | ($10) | 95% |
|
| EPS (TTM) | $2.405 | ($0.500) | 75% |
|
| Operating Cash Flow (TTM) (Mil) | $4,341 | ($2) | 94% |
|
| Net Cash Flow (TTM) (Mil) | $725 | $1 | 93% |
|
| Long-Term Debt (Q1) (Mil) | $10,988 | $22 | 92% |
|
| Enterprise Value (Q1) (Mil) | $103,074 | $304 | 96% |
|
| Valuation | BSX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.69 | 2.80 | 61% |
|
| P/E | 19.6 | 31.1 | 50% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.2 | 1.9 | 9% |
|
| Ratios | BSX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.3% | 59.1% | 81% |
|
| Net Margin | 17.5% | (7.3%) | 76% |
|
| ROA | 8.4% | (13.7%) | 84% |
|
| ROE | 14.8% | (15.8%) | 71% |
|
| Liabilities to Assets | 41.1% | 44.7% | 32% |
|
| F-Score | 7 | 4 | 84% |
|
Boston Scientific Corporation did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors